



1-16-07 ID/2133

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Gronborg et al.  
SERIAL NUMBER: 10/594,192 EXAMINER : Not Yet Assigned  
FILING DATE: September 25, 2006 ART UNIT : 2133  
FOR: THERAPEUTIC USE OF A GROWTH FACTOR, NSG33

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Copies of Cited References B1-B10; C1-C19; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 19313-015 NATL. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

A handwritten signature in black ink that reads "Christina K. Stock".

Ivor R. Elrifi, Reg. No. 39,529  
Christina K. Stock, Reg. No. 45,899  
Attorney(s) for Applicants  
c/o MINTZ, LEVIN  
Address all written correspondence to  
**Customer no.: 30623**  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Date: January 11, 2007



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Gronborg et al.

APPLICANT NUMBER:

10/594,192

EXAMINER :

Not Yet Assigned

FILING DATE:

September 25, 2006

ART UNIT :

2133

FOR:

THERAPEUTIC USE OF A GROWTH FACTOR, NSG33

**MAIL STOP AMENDMENT**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Gronborg et al.  
U.S.S.N.: 10/594,192

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 19313-015 NATL.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Christina K. Stock, Reg. No. 45,899

Attorney(s) for Applicants

c/o MINTZ, LEVIN

Address all written correspondence to

**Customer no.: 30623**


Tel: (617) 542-6000

Fax: (617) 542-2241

Date: January 11, 2007

TRA 2238846v.1

Express Mail No.: EV 869861409 US  
Date of Deposit: January 11, 2007



Page 1 of 2  
Attorney Docket No.: 19313-015 NATL

Please type a plus sign (+) in this box



PTO/SB (12-97)  
Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>		10/594,192	
				<b>Int'l Filing Date</b>		March 30, 2005	
				<b>First Named Inventor</b>		Gronborg	
				<b>Group Art Unit</b>		Not Yet Assigned	
				<b>Examiner Name</b>		Not Yet Assigned	
				<b>Attorney Docket Number</b>		19313-015 NATL	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>U.S. Patent Document No.</b>	<b>Issue Date</b>	<b>Name of Patentee(s) or Applicant(s)</b>	<b>Class</b>	<b>Sub Class</b>	<b>Filing Date If Appropriate</b>
<b>U.S. PUBLISHED APPLICATION DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>U.S. Published Application No.</b>	<b>Published Date</b>	<b>Name of Patentee(s) or Applicant(s)</b>	<b>Class</b>	<b>Sub Class</b>	<b>Filing Date If Appropriate</b>
<b>FOREIGN PATENT DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>Foreign Patent Document Office Number</b>		<b>Name of Patentee(s) or Applicant(s)</b>	<b>Date of Publication</b>	<b>Translation Yes No</b>	
	B1	WO	93/22437	N.V. INNOGENETICS S.A.	11/11/93		
	B2	WO	01/39786 A2	INNOGENETICS N.V.	06/07/01		
	B3	WO	01/54474 A2	HUMAN GENOME SCIENCES, INC.	08/02/01		
	B4	WO	01/55301 A2	HUMAN GENOME SCIENCES, INC.	08/02/01		
	B5	WO	01/55440 A1	HUMAN GENOME SCIENCES, INC.	08/02/01		
	B6	WO	01/57190 A2	HYSEQ, INC.	08/09/01		
	B7	WO	01/83510 A1	HUMAN GENOME SCIENCES, INC.	11/08/01		
	B8	WO	03/066877 A2	DIADEXUS, INC.	08/14/03		
	B9	WO	2004/035732 A2	FIVE PRIME THERAPEUTICS, INC.	04/29/04		
	B10	WO	2004/079014 A2	ARCTURUS BIOSCIENCE, INC.	09/16/04		
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.</b>					
	C1	GenBank, Accession No. AAM78739, November 6, 2001.					
	C2	GenBank, Accession No. AAM79723, November 6, 2001.					
	C3	GenBank, Accession No. ABB10367, January 10, 2002.					
	C4	GenBank, Accession No. ABB10537, January 10, 2002.					
	C5	GenBank, Accession No. ABA06589, January 10, 2002.					
	C6	GenBank, Accession No. ABA06759, January 10, 2002.					
	C7	GenBank, Accession No. ABB57447, March 15, 2002.					
	C8	GenBank, Accession No. ADP29324, August 12, 2004.					

	C9	GenBank, Accession No. BG806341, December 21, 2001.
	C10	GenBank, Accession No. CAB56188, September 17, 1999.
	C11	GenBank, Accession No. AAH00662, November 29, 2000.
	C12	GenBank, Accession No. NP_076947, February 27, 2001.
	C13	GenBank, Accession No. AAK61247, June 8, 2001.
	C14	GenBank, Accession No. AAH37181, September 23, 2002.
	C15	GenBank, Accession No. AAH88383, December 22, 2004.
	C16	Grønborg et al., "Identification of secreted neurotrophic factors using bioinformatics combined with expression analysis", program no. 825.2, abstract viewer/itinerary planner, Washington, DC: Society for Neuroscience (2005)
	C17	Mu et al., "Gene expression in the developing mouse retina by EST sequencing and microarray analysis", <i>Nucl. Acids Res.</i> , 29(24):4983-4993 (2001)
	C18	Navarro-Galvel et al., "HNSG33 effects on survival and differentiation of human neural stem cell-derived neuronal and glial progeny", program no. 248.14, abstract viewer/itinerary planner, Washington, DC: Society for Neuroscience (2005)
	C19	Nishino et al., "Meteorin: a secreted protein that regulates glial cell differentiation and promotes axonal extension", <i>EMBO J.</i> , 23(9):1998-2008 (2004)

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.